Mixed response to ipilimumab in a melanoma patient with brain metastases: Case report and review of the literature

Case Reports in Oncology

Volumn 6, Issue 1, 2013, Pages 229-235

  Feldmann, Georg ^a   Brossart, Peter ^a   Zipfel, Matthias ^a   Von Lilienfeld Toal, Marie ^a,b  

^a UNIVERSITY HOSPITAL BONN   (Germany)

^b JENA UNIVERSITY HOSPITAL   (Germany)

Author keywords

Brain metastases; Ipilimumab; Melanoma; Survival

Indexed keywords

ALPHA INTERFERON; ANTIHYPERTENSIVE AGENT; B RAF KINASE; IPILIMUMAB; LACTATE DEHYDROGENASE; PREDNISONE; TEMOZOLOMIDE; TUMOR MARKER;

ADJUVANT THERAPY; AGED; ALLELE; ARM; AUTOIMMUNE DISEASE; AXILLARY LYMPH NODE; BRAIN METASTASIS; CANCER GROWTH; CANCER IMMUNOTHERAPY; CANCER INFILTRATION; CANCER PATIENT; CANCER RADIOTHERAPY; CANCER STAGING; CASE REPORT; CAUDATE NUCLEUS; CERVICAL LYMPH NODE; CHEEK; COMPUTER ASSISTED TOMOGRAPHY; DIARRHEA; DISEASE COURSE; DRUG RESPONSE; EXCISION; FATIGUE; FRONTAL CORTEX; GENE MUTATION; HUMAN; HYPERTENSION; IRRADIATION; LACTATE DEHYDROGENASE BLOOD LEVEL; LEG; LIMB WEAKNESS; LOW DRUG DOSE; LUNG METASTASIS; LYMPH NODE; LYMPH NODE METASTASIS; MALE; MANDIBLE; MELANOMA; MULTIPLE CYCLE TREATMENT; NECK DISSECTION; NEUROLOGIC DISEASE; NUCLEAR MAGNETIC RESONANCE IMAGING; ONCOGENE RAS; PARESTHESIA; PAROTID GLAND; PRIORITY JOURNAL; REVIEW; SKIN METASTASIS; SOFT TISSUE METASTASIS; STEREOTACTIC TREATMENT; STEROID THERAPY; SYSTEMIC THERAPY; WILD TYPE;

EID: 84877998628     PISSN: None     EISSN: 16626575     Source Type: Journal    
DOI: 10.1159/000351125     Document Type: Review

References (17)

1. Nikolaou VA, Stratigos AJ, Flaherty KT, Tsao H: Melanoma: new insights and new therapies. J Invest Dermatol 2012;132(3 Pt 2):854-863.
2. Preusser M, Capper D, Ilhan-Mutlu A, Berghoff AS, Birner P, Bartsch R, Marosi C, Zielinski C, Mehta MP, Winkler F, Wick W, et al: Brain metastases: pathobiology and emerging targeted therapies. Acta Neuropathol 2012;123:205-222.
3. Kirkwood JM, Bastholt L, Robert C, Sosman J, Larkin J, Hersey P, Middleton M, Cantarini M, Zazulina V, Kemsley K, Dummer R: Phase II, open-label, randomized trial of the MEK1/2 inhibitor selumetinib as monotherapy versus temozolomide in patients with advanced melanoma. Clin Cancer Res 2012;18:555-567.
4. Patel PM, Suciu S, Mortier L, Kruit WH, Robert C, Schadendorf D, Trefzer U, Punt CJ, Dummer R, Davidson N, Becker J, et al: Extended schedule, escalated dose temozolomide versus dacarbazine in stage IV melanoma: final results of a randomised phase III study (EORTC 18032). Eur J Cancer 2011;47:1476-1483.
5. Robert C, Thomas L, Bondarenko I, O'Day S, Weber J, Garbe C, Lebbe C, Baurain JF, Testori A, Grob JJ, Davidson N, et al: Ipilimumab plus dacarbazine for previously untreated metastatic melanoma. N Engl J Med 2011;364:2517-2526.
6. Hodi FS, O'Day SJ, McDermott DF, Weber RW, Sosman JA, Haanen JB, Gonzalez R, Robert C, Schadendorf D, Hassel JC, Akerley W, et al: Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 2010;363:711-723.
7. Hodi FS, Butler M, Oble DA, Seiden MV, Haluska FG, Kruse A, Macrae S, Nelson M, Canning C, Lowy I, Korman A, et al: Immunologic and clinical effects of antibody blockade of cytotoxic T lymphocyte-associated antigen 4 in previously vaccinated cancer patients. Proc Natl Acad Sci USA 2008;105:3005-3010.
8. Schartz NE, Farges C, Madelaine I, Bruzzoni H, Calvo F, Hoos A, Lebbe C: Complete regression of a previously untreated melanoma brain metastasis with ipilimumab. Melanoma Res 2010;20:247-250.
9. Carson MJ, Doose JM, Melchior B, Schmid CD, Ploix CC: CNS immune privilege: hiding in plain sight. Immunol Rev 2006;213:48-65.
10. Prins RM, Vo DD, Khan-Farooqi H, Yang MY, Soto H, Economou JS, Liau LM, Ribas A: NK and CD4 cells collaborate to protect against melanoma tumor formation in the brain. J Immunol 2006;177:8448-8455.
11. Hodi FS, Oble DA, Drappatz J, Velazquez EF, Ramaiya N, Ramakrishna N, Day AL, Kruse A, Mac Rae S, Hoos A, Mihm M: CTLA-4 blockade with ipilimumab induces significant clinical benefit in a female with melanoma metastases to the CNS. Nat Clin Pract Oncol 2008;5:557-561.
12. Balakan O, Suner A, Yigiter R, Balakan T, Sirikci A, Sevinc A: Long-term survival in metastatic malignant melanoma: ipilimumab followed by vemurafenib in a patient with brain metastasis. Intern Med 2012;51:2819-2823.
13. Du Four S, Wilgenhof S, Duerinck J, Michotte A, Van Binst A, De Ridder M, Neyns B: Radiation necrosis of the brain in melanoma patients successfully treated with ipilimumab, three case studies. Eur J Cancer 2012;48:3045-3051.
14. Margolin K, Ernstoff MS, Hamid O, Lawrence D, McDermott D, Puzanov I, Wolchok JD, Clark JI, Sznol M, Logan TF, Richards J, et al: Ipilimumab in patients with melanoma and brain metastases: an open-label, phase 2 trial. Lancet Oncol 2012;13:459-465.
15. Margolin K: Ipilimumab in a phase II trial of melanoma patients with brain metastases. Oncoimmunology 2012;1:1197-1199.
16. Nieder C: Ipilimumab in patients with melanoma and brain metastases. Lancet Oncol 2012;13:e277, author reply e277-e278.
17. Di Giacomo AM, Ascierto PA, Pilla L, Santinami M, Ferrucci PF, Giannarelli D, Marasco A, Rivoltini L, Simeone E, Nicoletti SV, Fonsatti E, et al: Ipilimumab and fotemustine in patients with advanced melanoma (NIBIT-M1): an open-label, single-arm phase 2 trial. Lancet Oncol 2012;13:879-886.